9 February 2022 RE: Questions regarding Dilution, Share

New Post Public Reply Private Reply Replies (0) Message Board
tasher
394
9 February 2022

RE: Questions regarding Dilution, Share Structure, T trades, Financing and Progress

Dear Shareholders,

I am writing to update you on the points listed above.

Firstly, as we have stated previously, we once again wish to confirm that we are not aware of any dilution of our stock. There is the slight possibility that GPL Ventures, LLC (GPL) could still be holding shares, however we have zero visibility of this to confirm it. Regarding GPL however, we can assure Shareholders that they are under SEC oversight for anything that they do to exit their OTC positions. In simple terms, they are not able to dump or dilute stock as much as many are speculating.

Secondly, regarding the Share Structure, any shares that have been issued are ALL restricted shares for acquisitions as we have explained previously. All or certainly most companies go public to use their shares as currency to raise capital and/or acquire businesses/assets. To confirm again, we have not issued any free trading shares for capital or the acquisition of businesses. Any shares that have been issued for deals or to funders have been restricted shares, which are mostly restricted for two years. In this regard, we once again would like to reassure you that there is no dilution going on.

Thirdly, regarding the T trades, we are not behind them, and we have no idea who is responsible for them. For some reason, our stock has been and is still being heavily manipulated. We also assume that there is similar manipulation going on with DRCR’s stock, which could be a related and coordinated plan to drive down the ILUS balance sheet. Although the spreading of rumors to drive down the price of a stock is both an unethical and illegal practice, it is clearly what is going on with our stock. Once again, let me assure you that we are not behind any of these tactics.

I would like to confirm that we have secured in the region of $10 million of additional financing with two reputable funds. The funding which has already commenced, was secured against medium and long-term, non-toxic promissory notes as well as some restricted shares which have been issued. We are pleased to say that this financing will eliminate GPL as a noteholder from the company, and funds will be deployed for further expansion of the company. Both funders are renowned financial partners of emerging companies, such as ILUS. They are known for supporting companies to refinance on better terms, remove historic toxic debt, and strengthen their balance sheets. ILUS’ consistent growth, recent delivery of several key milestones and the trading volume of its stock are some of the multiple factors that have allowed us to negotiate beneficial terms for ILUS and its Shareholders.

The capital will help us to expand our manufacturing and distribution capability, and to complete our next round of acquisitions, given that we are coming to the completion of the current round in the next few days. In addition, the funding will also play a role in the consolidation of our current and upcoming businesses, such as for the hiring of new key staff, implementation of new integrated software, to conduct further R&D and much more.

We had previously spoken of announcing short and medium-term news. We then adapted our strategy to avoid giving warning to the retail investors who tend to “sell on the news”. I would like to clarify that we do have several significant short and medium-term announcements to make, and Shareholders have a great deal to look forward to over the coming days, weeks, and months.

Finally, regardless of the manipulation of our stock, I would like to reassure Shareholders that ILUS is in great shape. We have successfully identified and completed several acquisitions and are in the process of completing several more. We are having a record period now with sales ramping up and massive contracts in negotiation. Simultaneously, we are reducing costs through scale and efficiency. We are also in the process of growing our Marketing team and the offering for each of our new acquisitions and current products. Simply put, all areas of the business are getting taken to the next level.

Thank you for your continued support.

Yours sincerely,

Nick

https://data-room.center/Data/ILUS/Letters/Le...092022.pdf


On a side not
I am a member of the ILUS Disord and if you would like to join here is a link for you to use https://discord.gg/GAr9KwwkR8

Ilustrato Pictures International Inc. (ILUS) Stock Research Links

ILUS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading